Johnson & Johnson alternatives

Major competitors with robust oncology portfolios include Roche, Novartis and Merck. Each maintains late-stage assets in targeted therapies and immunotherapies, often with different combination strategies and regional approval timelines compared to Johnson & Johnson’s multiple myeloma and solid tumor programs.

Medtronic, Stryker and Zimmer Biomet offer overlapping orthopaedic implants and robotic-assisted surgery systems. They frequently compete on hospital pricing, software ecosystem lock-in and clinical evidence volume, sometimes providing more modular hardware options than J&J’s integrated platforms.

AbbVie and UCB concentrate resources on immunology with fewer therapeutic distractions. Their pipelines emphasize next-generation antibodies and oral agents, delivering potentially quicker iteration cycles and different partnership models than J&J’s broad immunology franchise.

Abbott and Boston Scientific frequently position mid-tier cardiovascular devices at lower acquisition costs for health systems while matching or exceeding J&J on certain stent and valve technologies, though global distribution footprints remain smaller.

Alcon and Bausch + Lomb provide competing intraocular lenses, surgical equipment and consumer eye health lines. They often emphasize specialized cataract and refractive portfolios with distinct surgeon training programs and regional pricing flexibility.

Intuitive Surgical and Medtronic’s digital surgery units offer advanced robotic and analytics platforms. They provide deeper software ecosystems and recurring revenue models that some hospital networks prefer over J&J’s hardware-centric approach.